Calendar

An AMCP and Optum^® Corporate Training Program

Medicare Advantage is the fastest-growing line of business for many health plans. With increasingly more plans on the market, the CMS Star Ratings are important. Introduced in 2008, the ratings were part of a system-wide push to improve quality of care, patient and member experience, and value-based payments. The original intent behind the Star Rating system was to help enrollees make informed health insurance decisions, however, the quality bonus payment has driven health plans to create member and provider strategy targeting Star Ratings measures. By understanding how the current Medicare Star Rating program is designed and the challenges and incentives created for plan sponsors, life science companies looking for opportunities to partner can prepare an informed approach to their value proposition.

An AMCP and Xcenda Corporate Training Program.

This program offers real-world, relevant training for life science companies. Are your company’s pre-approval information exchange (PIE) strategy and tactics aligned with the market and FDA guidance? Do you know: 

• What PIE data payers are receiving about new products in development? 
• What additional data payers are looking for? 
• What additional information are payers providing about specialty products? 
• How other manufacturers are communicating PIE information? 
• How to leverage FormularyDecisions^SM for pre-approval communication? 
• How to integrate a pre-approval dossier into a proactive communications plan? 
• How to facilitate alignment on PIE policies and process with key stakeholders within your company ?

An AMCP and Milliman Corporate Training Program

Join leading managed care and health plan experts for an interactive training that translates medical benefit management into new opportunities for you and your customers. With AMCP faculty and Milliman professionals, you will receive: 

• An interactive self-paced e-Learning training program designed to fit into your busy schedule and deliver the basics with eight 40-minute modules.  This program is designed to deliver the fundamental knowledge on the basics of medical benefits medication management. The program includes an overview of today’s key trends and challenges and provides insights and solutions. 

• One day remote learning training from experts in managed care and health plans to gain knowledge and actionable insights in medical benefits medication management.  

The role of digital therapies in preventing, managing, and treating medical conditions has evolved greatly in the past few years. They may be used independently or taken in tandem with other therapies to optimize clinical outcomes for patients. As innovative therapies are introduced into the market, challenges with developing evidence-based coverage criteria and tracking utilization have been identified. Forum participants will outline key barriers and develop solutions to support the appropriate use and coverage of digital therapeutics in the health care system.

This event is invitation only. If you're interested in participating, please email corpopportunities@amcp.org.

An AMCP and Precision Value & Health Corporate Training Program

Over the last four –to five years, the market has seen the launch of numerous cell and gene therapies including Yescarta, Kymriah, Luxterna, and Zolgensma to name a few. The market for cell and gene therapy is poised to expand exponentially with over 1,100 cell and gene therapy companies who are actively conducting over 1,000 clinical trials.

Cell and gene therapies present tremendous clinical and humanistic opportunity to change the course of disease but also present several unique aspects that differ from more traditional therapies and can even differ between cell and gene therapy. These differences will impact how innovators develop evidence, manufacturing, and distribution capabilities and payers assess value, make coverage decisions and manage reimbursement.

Our half-day course will provide foundational information to equip the audience with how to best develop a compelling evidence package for cell and gene therapies, how payers will apply their assessment in decision-making, and how to best bridge the gap between these two. The program will be structured with a mixture of presentations and panel discussions.

Drug development is expensive, time consuming, and risky. To address these factors, clinical and regulatory experts in pharmaceutical companies must design drug development programs and clinical trials that meet FDA requirements. Especially with drugs approved via expedited pathways, the payers’ perspective typically takes a back seat to FDA approval criteria. Further, payer expectations for efficacy and safety, as well as population parameters, can differ from those established to meet FDA stipulations. However, meeting payers’ expectations is critical for patient access and commercial success. Payers increasingly demand demonstration of long-term value, especially for high investment medications or those with a high-risk safety profile. Despite the rigorous steps in the process of drug development, limitations exist due to the difference between FDA approval requirements and payer evidence needs. Forum participants will outline payer needs, barriers, and solutions for products approved through an expedited approval process regarding evidence for new drug products.

This event is invitation-only. If you're interested in participating, please email corpopportunities@amcp.org.